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Summary
Suppose that we need to classify a population of subjects into several well-defined ordered risk
categories for disease prevention or management with their “baseline” risk factors/markers. In
this article, we present a systematic approach to identify subjects using their conventional risk
factors/markers, who would benefit from a new set of risk markers for more accurate classification.
Specifically for each subgroup of individuals with the same conventional risk estimate, we present
inference procedures for the reclassification and the corresponding correct re-categorization rates
with the new markers. We then applied these new tools to analyze the data from the Cardiovas-
cular Health Study sponsored by the US National Heart, Lung, and Blood Institute (NHLBI).
We used Framingham risk factors plus the information of baseline anti-hypertensive drug us-
age to identify adult American women who may benefit from the measurement of a new blood
biomarker, CRP, for better risk classification in order to intensify prevention of coronary heart
disease for the next ten years.
Keywords: Coronary Heart Disease, Nonparametric Functional Estimation, Risk Factors/Markers,
Pointwise and Simultaneous Confidence Interval, Subgroup Analysis.
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1. INTRODUCTION
An integral part of evidence-based guidelines for disease prevention or management is a well-
defined risk classification rule, which assigns each subject from a population of interest to one
of several ordered risk groups. The assignment is based on the individual risk, the chance that
the subject will experience a specific type of events during a given time period. Appropriate
interventions will then be offered to subjects in each risk category. The risk is estimated using
a scoring system with the subject’s “conventional” baseline risk factors/markers. For example,
in the United States more than a half million women die of cardiovascular diseases (CVD) each
year and the majority of such deaths are due to coronary heart disease (CHD). Recently, the
American Heart Association (AHA) issued guidelines for prevention of CHD in adult women
(Mosca et al., 2004; 2007). Specifically, risk categories are defined by the individual’s predicted
risk of having a CHD event in the next ten years. Adult American women are classified as
being low risk (< 10%), intermediate risk (between 10% and 20%), or high risk (≥ 20%). Such
risk threshold values have also been employed by the Adult Treatment Panel III (ATP III) of
the National Cholesterol Education Program to develop an evidence-based set of guidelines on
cholesterol management (Grundy et al., 2004). For subjects with intermediate or high risk,
certain life style and pharmacologic interventions are recommended. The risk is estimated using
a modified version of the Framingham Risk Score (FRS), which is a multivariate risk equation
based on traditional risk factors such as age, blood cholesterol, HDL cholesterol, blood pressure,
smoking status and diabetes mellitus (Wilson et al., 1998).
Now, suppose that new risk markers for such future events are available, and they may
potentially improve the conventional risk estimation. Measuring these markers, however, may
be invasive or costly. Under various settings, novel procedures have been proposed to quantify
the overall incremental benefit from the new markers for the entire population of interest (Pepe
et al., 2004; Cook, 2007; Tian et al., 2007; Uno et al., 2007; Pepe et al., 2008; Pencina et al.,
2008). In a recent paper, Wang et al. (2006) concluded that almost all new contemporary
biomarkers for prevention of CHD added rather moderate overall predictive value to FRS.
2
http://biostats.bepress.com/harvardbiostat/paper91
In general, for subjects whose conventional risk estimates are either low or high, clinical prac-
titioners would not require new markers for their decision making. Unfortunately, rather little
research has been done for developing a systematic procedure to identify a subset of individuals
who would benefit significantly from measurement new risk markers (D’Agostino, 2006). With
respect to the aforementioned risk classification rule recommended by the AHA and ATP III,
recently Cook et al. (2006) and Ridker et al. (2007) examined the incremental value of a new
blood biomarker, the C-Reactive protein (CRP) measured by a highly sensitive assay, with a co-
hort of subjects from the Women’s Health Study (Buring & Hennekens, 1992). They concluded
that subjects whose traditional risk scores are between 5% and 20% would benefit from this
marker. Their claims, however, were based on the reclassification rates with CRP among four
highly discretized subgroups of the entire cohort based on conventional risk estimates. Moreover,
it is not clear how to quantify the gain of reclassification solely based on the observed event rates
for the risk categories.
In this article, for each subject in the study we construct two individual risk estimates,
one based on the conventional risk markers and the other based on the conventional and new
markers. A subject may be reclassified into a different risk category with the new risk estimate.
For the subset D of subjects with the same conventional risk estimate, we obtain consistent
nonparametric functional estimates for the reclassification rates and their corresponding standard
error estimates. Note that large observed reclassification rates do not automatically imply that
the new markers are important for subjects in D. Consistent estimates for the proportions of
subjects who are reclassified correctly are also needed for cost-benefit decision making. In this
paper, we develop procedures for making inference about such proportions. Furthermore, we
propose a test procedure to examine whether reclassifications by the new markers are better
than “random allocations” of subjects in D.
As an illustration, consider the set D consisting of individuals who have the same conventional
FRS estimate of 9% for experiencing CHD events within ten years. Based on the aforementioned
prevention guidelines, individuals with this predicted risk would not be recommended for lipid-
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lowering drug therapy at present. Now, suppose that with the new markers, the estimate for
the proportion of subjects in D reclassified to the next higher risk category is 25%, and the
corresponding rate estimate for subjects in D, who are reclassified and had CHD events, is 3%.
The potential benefit with the new markers would be preventing 3% of subjects in D from
having future CHD events. However, the costs consist of measuring new marker values for every
subject in this subset, and giving possibly long-term, potentially toxic interventions to 25% of
the individuals. Even if we decide that for this scenario, the benefit outweighs the cost, we still
need to know whether this reclassification scheme is better than a “random allocation” process.
If we randomly move 25% of subjects in D to the next higher risk class, on average, 9% of these
subjects would have CHD events. The question is whether the observed 12% (3% out of 25%) is
significantly different from this null value of 9%.
The new proposal is illustrated with a data set from the Cardiovascular Health Study (CHS)
sponsored by the US National Heart, Lung and Blood Institute (Fried et al., 1991). This study
is a prospective, population-based, long term follow-up cohort study to determine risk factors for
predicting coronary future heart disease and stroke in adults 65 years or older. There were 5888
study subjects recruited between 1988 and 1993. For our analysis, we only considered data from
3393 female participants. For each subject, we utilized the risk factors/markers values at her
entry time to the study and her CHD event time by year 2003. The binary response variable is
whether the subject had experienced a CHD event (non-fatal MI, angina or CHD-related death)
during ten year follow-up. For this data set, the median age at the baseline is 72.5 and there
is no loss of follow-up for these endpoints. During the first 10 year follow-up, 19.5% of female
participants experienced non-fatal MI, angina or CHD-related death. On the other hand, 37% of
them died from non-CHD-related diseases. Among 3393 subjects, 52% of them survived by year
2003. In our analysis, the conventional risk factors consist of the Framingham risk factors and the
anti-hypertensive drug usage. The new marker considered here is CRP. For the risk classification
rule recommended by the ATP III, the CRP provides pointwise significant incremental values
for subjects whose conventional risk estimates are around 10% and 20% . On the other hand,
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we cannot find any subgroup of individuals who would benefit from the new marker under the
simultaneous inference setting when controlling the overall family-wise type I error rate of 0.05.
In the next section, we describe our proposed procedures for quantifying the incremental value
of new markers. Procedures for making inference about the incremental values were proposed
in Section 3. The results from analyzing the CHS data are detailed in Section 4. Concluding
remarks are given in Section 5.
2. QUANTIFYING INCREMENTAL VALUES FROM NEW MARKERS
Consider a subject randomly drawn from the study population. Let Y be its binary response
variable, U be the set of conventional markers and V be the set of new markers. Let p(U) =
pr(Y = 1| U) and p(U, V ) = pr(Y = 1| U, V ), the risks of this subject conditional on U and
{U, V }, respectively. Assume that the classification rule assigns each subject to one of L ordered
risk categories {C1, · · · , CL}. A subject is classified to Cl, if its risk for Y = 1 is in the interval
[νl−1, νl), where l = 1, · · · , L, and 0 = ν0 < · · · < νL = 1. Based on p(U, V ), the subject may be
reclassified into a higher or lower risk category.
Now, suppose that the data {(Yi, Ui, Vi), i = 1, · · · , n} consist of n independent copies of
(Y, U, V ). In theory, for any given (u, v), the probabilities p(u) and p(u, v) may be consistently
estimated nonparametrically. In practice, however, such nonparametric functional estimates do
not behave well even when the dimension of U or V is not small. A practical alternative is to
consider a working model for approximating p(U) by a parametric model
g1(β
′X), (2.1)
where X, a p × 1 vector, is a function of U, β is unknown vector of parameters and g1(·) is a
known, smooth, increasing function. Now, suppose that β is estimated by β̂ via an estimating
function S1(β). The risk for a subject with U = u, whose X = x, is estimated by p̂u = g1(β̂
′x).
With the additional marker set V, consider the working model for approximating p(U, V ) by
g2(γ
′W ), (2.2)
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whereW, a r×1 vector, is a function of U and V, g2(·) is a known, smooth, increasing function, and
γ is a vector of unknown parameters. Let γ be estimated by γ̂ via an estimating function S2(γ).
For a subject with (U, V ) = (u, v) whose W = w, the estimated risk is p̂{u,v} = g2(γ̂′w). Note
that when Models (2.1) and (2.2) are correctly specified, with reasonable estimating functions
S1(·) and S2(·), p̂u and p̂{u,v} are consistent estimators for p(u) and p(u, v), respectively.
Now, consider a random future subject with (Y, U, V ) = (Y 0, U0, V 0). For a given 0 < s < 1,
let Ds be the group of future subjects whose p̂U0 = s. For subjects in Ds with additional new
marker information, the probability of a subject being classified to Cl with Y
0 = q, is
η
(q)
l (s) = pr
{
p̂{U0,V 0} ∈ [νl−1, νl), Y 0 = q
∣∣ p̂U0 = s} , for q = 0, 1; l = 1, ..., L. (2.3)
Here, the conditional probabilities are with respect to the data {(Yi, Ui, Vi)}, Y 0, U0 and V 0.
The probability of a subject being classified to Cl is ηl(s) = η
(0)
l (s) + η
(1)
l (s). It is important
to note that large reclassification rates ηl(s) do not automatically imply that the new markers
are valuable for Ds. The (2.3) also plays an important role in cost-benefit decision making. For
subjects who are re-assigned to a higher risk category, {η(1)l (s), l > ls} provides us the proportion
of subjects in Ds who would benefit from the new markers, where ls =
∑L
l′=1 I(νl′ ≤ s). On the
other hand, for subjects who are moved down to a lower risk group, {η(0)l (s), l < ls} would reflect
the incremental gain.
Moreover, it is important to know whether the above reclassification is more than a purely
random allocation process. Specifically, if the new markers contribute nothing to the classification
rule, one would expect that conditional on p̂U0 = s, p̂{U0,V 0} is independent of Y 0. That is,
η
(1)
l (s) = ηl(s)× ξ(s), l = 1 · · · , L, (2.4)
where ξ(s) = pr(Y 0 = 1| p̂U0 = s) =
∑L
l=1 η
(1)
l (s). The differences
{Dl(s) = η(1)l (s)− ηl(s)ξ(s), l = 1, ..., L} (2.5)
also play important roles for quantifying the incremental value of the new markers for future
subjects in Ds. In fact, if the ratios, {η(1)l (s)/ηl(s)}, increase in l, l = 1, · · · , L, this indicates that
the markers indeed provide extra information about risk classifications of these subjects.
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3. ESTIMATING η
(q)
l (s) WITH POSSIBLY CENSORED EVENT TIME
OBSERVATIONS
Oftentimes the binary response Y indicates that either the event time of interest is greater or
less than a specific time point via a long term follow-up study. To this end, Let T0 be the random
event time and t0 be a prespecified time point. Here, the binary variable Y = 1, if T0 < t0; 0,
otherwise. The “response” Y may not be observed directly due to censoring. That is, T0 may
be censored by a random variable C. Let G(·) be the survival function of C. In this article, we
assume that G(·) is independent of T0, U and V. For T0, one can only observe T = min(T0, C)
and ∆ = I(T0 ≤ C), where I(·) is the indicator function. Our data {(Ti,∆i, Ui, Vi), i = 1, · · · , n}
consist of n independent copies of (T,∆, U, V ). Note that if there is no censoring involved,
G(·) = 1 and {Yi, i = 1, · · · , n} can be observed completely.
To obtain the estimates p̂u and p̂{u,v}, one may assume proportional hazards working models
for T0 with U, and then for T0 with U and V. With the maximum partial likelihood estimates for
the regression coefficients and the estimates for the underlying cumulative hazard functions, we
can estimate p(u) and p(u, v). However, if a working proportional model is not correctly specified,
the regression coefficient estimator converge to a constant vector, as n→∞, which may depend
on the censoring distribution. Moreover, a good prediction model for short term survivors may
not work well for predicting long term survivors. In this article, instead of modeling the entire
hazard function of T0, we use the approach taken by Uno et al. (2007) to model the conditional
risks of experiencing an event by t0 directly via (2.1) and (2.2).
To estimate β in (2.1), we let the estimating function S1(β) be
n∑
i=1
ω̂iXi {I(Ti < t0)− g1(β′Xi)} =
n∑
i=1
ω̂iXi {Yi − g1(β′Xi)} , (3.1)
where the weighting ω̂i = ∆iI(Ti < t0)/Ĝ(Ti) + I(Ti ≥ t0)/Ĝ(t0), and Ĝ(·) is the Kaplan-
Meier estimator of G(·) Here, the weighting takes care of the problem due to censoring and
I(Ti < t0) = Yi when ω̂i 6= 0. It is shown in Uno et al. (2007) that as n → ∞, the resulting
estimator β̂ converges to a constant which is free ofG(·) even when the model (2.1) is misspecified.
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Similarly, with additional V and Model (2.2), one can use the estimating function
S2(γ) =
n∑
i=1
ω̂iWi {Yi − g2(γ′Wi)} (3.2)
to estimate γ.
Now, since η
(q)
l (s) is between 0 and 1, we use a non-parametric local logistic likelihood esti-
mation procedure to obtain consistent estimator η̂
(q)
l (s). Specifically, first consider a kernel-type
nonparametric functional estimator based on the local likelihood “score” function for the stan-
dard logistic regression which relates the binary response I{p̂{Ui,Vi} ∈ [νl−1, νl), Yi = q} to the
regressor Êi(s) = ψ(p̂Ui)− ψ(s). Here, we choose a proper transformation ψ(p̂U) of p̂U to imple-
ment the smoothing, where ψ(·) is a known, non-decreasing function (Wand et al., 1991; Park
et al., 1997). For any given s, l and q, this results in a score function of the intercept parameter
a and slope parameter b:
n∑
i=1
 1
h−1Êi(s)
Kh{Êi(s)}ω̂i[I{p̂{Ui,Vi} ∈ [νl−1, νl), Yi = q}− g0{a+ bÊi(s)}], (3.3)
where g0(x) = exp(x)/{1 + exp(x)}, Kh(x) = K(x/h)/h, K(·) is a known smooth symmetric
kernel density function with a bounded support, and the bandwidth h > 0 is assumed to be
O(n−v), for 1/5 < v < 1/2. Let η̂(q)l = g0(â), where â is the resulting estimator of the intercept
by solving the equations: (3.3)=0, for q = 0, 1 and l = 1, · · · , L. Then ηl(s) and ξ(s) can be
estimated by η̂l(s) = η̂
(1)
l (s) + η̂
(0)
l (s) and ξ̂(s) =
∑L
l=1 η̂
(1)
l (s), respectively.
In Appendix A, we show that η̂
(q)
l (s) − η(q)l (s) → 0 in probability, uniformly in s ∈ Ωh ≡
[ψ−1(ρl + h), ψ−1(ρr − h)], where [ρl, ρr] is a subset of the support of ψ{g1(β′0X)} and β0 is the
limit of β̂. Furthermore, we show in Appendix B that for large n, the joint distribution of
{(nh)1/2{η̂(q)l (s)− η(q)l (s)}, q = 0, 1; l = 1, · · · , L}
can be approximated by the conditional distribution of a mean-zero normal vector{
n−1/2h1/2
n∑
i=1
Kh{Êi(s)}V̂(q)li (s)Zi, q = 0, 1; l = 1, · · · , L
}
, (3.4)
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given the data, where
V̂(q)li (s) =
ω̂i[I{p̂{Ui,Vi} ∈ [νl−1, νl), Yi = q} − η̂(q)l (s)]
τ̂{ψ(p̂Ui)}
,
τ̂(s) =
∑n
i=1Kh{Êi(s)}/n is the estimated density function of ψ(p̂U) and {Zi, i = 1, · · · , n}
is a random sample from the standard normal variable and is independent of the data. Note
that the {Zi, i = 1, · · · , n}, are the only random quantities in (3.4), whose distribution can be
approximated easily by simulating {Zi, i = 1, · · · , n} repeatedly. Confidence interval estimates
for {η(q)l (s)} and {ηl(s)} can be constructed via this large sample approximation.
Lastly, we need to examine whether the above reclassifications are better than realizations
from a random allocation scheme. To this end, we test the hypothesis that Dl(s) = 0, l =
1, · · · , L, defined in (2.5). Since we are interested in an alternative hypothesis that the ratios
{η(1)l (s)/ηl(s), l = 1, ..., L}, are non-decreasing in l, we consider a “trend” test statistic
D̂(s) =
L∑
l=1
w˜lD̂l(s), (3.5)
where w˜l is a set of pre-specified non-negative, increasing constants (Cochran, 1954; Armitage,
1955) and D̂l(s) = η̂
(1)
l (s) − η̂l(s) × ξ̂(s), for l = 1, · · · , L. Without loss of generality, we let∑L
l=1 w˜l = 1. Under the null hypothesis, (nh)
1/2D̂(s) is asymptotically equivalent to
(nh)1/2
L∑
l=1
w˜l
[
η̂
(1)
l (s)− η(1)l (s)−
1∑
q=0
{
η̂
(q)
l (s)− η(q)l (s)
}
ξ̂(s)
−
L∑
l′=1
{
η̂
(1)
l′ (s)− η(1)l′ (s)
}
η̂l(s)
]
. (3.6)
The null distribution of D̂(s) can be obtained by approximating all (nh)1/2{η̂(q)l (s)− η(q)l (s)} in
(3.6) via (3.4). A large observed D̂(s) suggests a rejection of the null hypothesis. Note that
the choice of the cutoff point for the above test is based on controlling Type I error rate at this
specific value s.
To control the overall family-wise Type I error rate for s ∈ Ωh under the simultaneous
inference framework, one may consider the test statistic Ŝ = sups∈Ωh D̂(s). Unfortunately,
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{D̂(s), s ∈ Ωh} does not converge in distribution as a process and Ŝ → ∞ in probability as
n → ∞. Therefore, we cannot use the standard large sample theory for stochastic processes
to obtain a finite sample approximation to the distribution of Ŝ. On the other hand, by the
strong approximation arguments and extreme value limit theorem (Bickel & Rosenblatt, 1973),
in Appendix C, we show that under the null hypothesis, a standardized version of Ŝ converges
in distribution to a proper random variable. In practice, for finite sample size n, one can ap-
proximate the null distribution of Ŝ by approximating (nh)1/2{η̂(q)l (s) − η(q)l (s)} in (3.6) with
(3.4) as we did for the above pointwise large sample approximation, but using the same set of
perturbation variables {Zi, i = 1, · · · , n} for all s ∈ Ωh. For each realized set of {Zi}, we obtain
a realization of the approximation to the distribution of Ŝ. The one-sided p value can then be
calculated via the observed Ŝ and the empirical distribution of the above realizations obtained
by generating the set of {Zi} repeatedly.
As for any nonparametric functional estimation problem, the choice of the smooth parameter
h is crucial for making inferences about η
(q)
l (s), ηl(s) and Dl(s). Here, we propose to use the
standard K-fold cross validation procedure to obtain an “optimal” h. Specifically, we randomly
split the data into K disjoint subsets of about equal sizes denoted by {Jk, k = 1, · · · , K}. For
each k, we use all observations which are not in Jk to estimate p(u) and p(u, v) by fitting the
working models (2.1) and (2.2) and then with a given h, to estimate η
(q)
l (s). Let the resulting
estimators be denoted by p̂(k)u, p̂(k){u,v} and η̂
(q)
l(k)(s). We then use the observations from Jk to
calculate the prediction error
PE(q)(k, l) =
∑
j∈Jk
ω̂j
[
I{p̂(k){Uj ,Vj} ∈ [νl−1, νl), Yj = q} − η̂(q)l(k){p̂(k)Uj}
]2
. (3.7)
Lastly we sum (3.7) over k = 1, · · · , K, and then choose h by minimizing this sum ofK prediction
errors. Note that the optimal smooth parameter value may only work for this specific (l, q) of
η̂
(q)
l (s). Alternatively, one may obtain a uniform bandwidth, which minimizes the sum of (3.7) over
k, but also over q = 0, 1, and l = 1, · · · , L. The order of such a bandwidth estimator is expected to
be n−1/5 (Wand & Jones, 1995; Fan & Gijbels, 1996) and thus the final bandwidth for estimation
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can be obtained by multiplying the estimated bandwidth by n−d0 , for some d0 ∈ (0, 3/10).
4. EXAMPLE
We apply the proposed procedures to analyze the data from female participants in the Cardio-
vascular Health Study (CHS) with respect to the risk classification rule recommended by AHS.
There are two different ways to define the binary response variable Y. First, a study subject
died before her ten-year follow-up from a non-CHD cause, we let Y = 0 (no CHD event). If the
subject had experienced a CHD event (non-fatal MI, angina or CHD-related death), let Y = 1.
There are no loss-to-follow-ups for these endpoints, therefore, we observe all Y ’s in this analysis.
For the second analysis, we let the time to death of other causes be an independent censoring
variable C for the time to the CHD event.
For both analyses, we consider an additive model (2.1) with g1(·) being the anti-logit function.
The vector X consists of the usage of hypertensive medication and all variables used in the model
for deriving the FRS given in Wilson et al (1998). Specifically, the FRS model includes various
dummy variables indicating levels of blood pressure, total cholesterol, and HDL, as well as age,
age2, present smoking status and diabetic status. Next, we fit the data using an additive model
(2.2) with g2(·) being the anti-logit function and W being the above risk factors/markers X and
the log-transformed CRP variable. For estimating functions (3.1) and (3.2), the estimator Ĝ(·)
is the standard K-M estimator with all death and CHD event times as censored observation for
censoring variable C. For the nonparametric function estimation, we letK(·) be the Epanechnikov
kernel, and ψ(·) = g−11 (·). The smoothing parameter h = 0.13 was obtained through the 10-fold
cross validation scheme. Specifically, we let h be the minimizer of
∑3
l=1
∑10
k=1
∑1
q=0 PE
(q)(k, l) in
(3.7) for both η̂
(0)
l (s) and η̂
(1)
l (s) multiplied by a normalizing constant n
−1/20. To approximate
the distributions of these estimators, we used the resampling method (3.4) with 500 independent
realized samples of {Zi, i = 1, · · · , n}.
For the case that there is no censoring involved, we present the results of our analysis in
Figure 1. Part (a) of the Figure is a smoothed density estimate for p̂U , which provides useful
11
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information regarding the relative size of the subgroup Ds of subjects such that p̂U0 = s. Here,
we choose the 1th and 99th percentiles of the empirical distribution of {β̂′Xi, i = 1, · · · , n}
as the boundary points ρl and ρr, respectively. Therefore, the results presented here are for
p̂U = s ∈ [0.074, 0.46]. Part (b) of the Figure gives the estimated re-classification rates over
p̂U . The green, blue and red curves are for the risk categories C1, C2 and C3, respectively. It
appears that there are substantial re-allocations with the CRP around the boundary points for
the risk classification rule. The solid green curve in Part (c) gives the estimates η̂
(1)
1 (s). Each
estimate is the proportion of subjects in Ds, who were reclassified to C1 and had CHD events.
The dotted green curve is the corresponding set of their “expected” estimates η̂l(s)× ξ̂(s) when
the re-categorizations are simply generated via a random allocation process. It appears that the
differences between these two curves are rather small. Parts (d) and (e) of the Figure are the
corresponding estimates for the risk categories C2 and C3. Part (f) is the curve of the p-values
based on the test statistic D̂(s) in (3.5) with weight w˜l = l/6. Part (f) suggests that from the
statistical point of view the subjects with conventional risk estimates p̂U ∈ [0.099, 0.107] and
p̂U ∈ [0.161, 0.215] may benefit from having CRP measurement at the (pointwise) significance
level of 0.05. For simultaneous inference, in Part (f) we also present the p-value curve using
Ŝ proposed in Section 3. With an overall Type I error rate of 0.05, there is no subgroup of
individuals who would benefit from the additional CRP information. That is, we cannot claim
that the reclassifications to risk categories by the new marker are not generated from a random
allocation process.
In Table 1(a), we present the results in details with s = 0.11, 0.18, 0.21 at which the pointwise
p-values based on the test D̂(s) are less than 0.05. Specifically, for each s, we provide the estimates
η̂l(s), η̂
(1)
l (s) and η̂
(0)
l (s), along with their sampling standard errors. For example, the subjects
with p̂U = 0.11 would be classified into the intermediate risk category based on the conventional
risk factors/markers. By including the additional CRP information, these subjects are further
stratified into the two risk categories: 37.9% (s.e. = 2.5%) down to the low risk category and
62.1% (s.e. = 2.5%) remaining in the intermediate risk category. As discussed in Section 2, not
12
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all reclassifications are correct. For the present case, 34.9% of the subjects in Ds are accurately
reclassified downward since these subjects would not develop an event within 10 years.
For the second set of analysis by treating non-CHD death as censoring, 18.8% of subjects are
censored with respect to the CHD events of interest. For this case, the smoothing parameter
is 0.2 via the 10-fold cross validation by minimizing
∑3
l=1
∑10
k=1
∑1
q=0 PE
(q)(k, l) in (3.7) with
normalizing constant n−1/20. We present the results in Figure 2 and Table 1(b) for p̂U = s ∈
[0.079, 0.63] under the same settings as in Figure 1 and Table 1(a). The regions for which the
CRP may be helpful are similar to those from the first set of analysis with the additional possible
region near p̂U = 0.30. However, the magnitude of gain is rather minimal near p̂U = 0.30 given
the small reclassification rate. Again, after controlling for the overall family-wise type I error
rate of 0.05, there does not appear to be a region with significant gain from CRP.
5. REMARKS
In this article, we present a systematic approach to quantify the added value from new risk
markers for classifying subjects into pre-specified risk categories. At each estimated conventional
risk level, we provide point and interval estimates for the reclassification rates along with the
corresponding proportions of accurate re-assignment for this subgroup of individuals. These
quantities play vital roles for cost-benefit analysis even when the cost of measuring the new
markers is not an issue or the re-categorization via the new markers is not generated from a
random allocation process. In general, if the new markers improve the risk prediction and change
the risk estimates drastically, one may expect the new marker to be helpful in risk reclassification
for the entire population. However, in most practical settings, we expect that subjects whose
conventional risk estimates are not around the risk threshold values would not benefit much from
the new markers with respect to a better assignment of risk category. This is indeed confirmed
with the results from extensive analysis of the data from the Cardiovascular Health Study. Thus,
to optimize the usage of the new markers for risk classification, one may consider ascertaining the
new markers only for subjects with conventional risk estimates in a certain range. Our proposed
13
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procedure provides a systematic approach to identifying the subgroups for which the new marker
improves risk classification.
14
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Appendix
Throughout, unless noted otherwise, we use the notation ' to denote equivalence up to op(1)
uniformly in s, . to denote being bounded above up to a universal constant, and F˙(x) to denote
dF(x)/dx for any function F . We use Pn and P to denote expectation with respect to the
empirical probability measure of {(Ti,∆i, Xi,Wi), i = 1, · · · , n} and the probability measure of
(T,∆, X,W ), respectively. Similarly Gn = n
1
2 (Pn − P).
Let β0 and γ0 denote the solution to the equations E[Xi{I(T0i < t0) − g1(β′Xi)}] = 0 and
E[Wi{I(T0i < t0) − g2(γ′Wi)}] = 0, respectively. Let p¯U = g1(β′0X). We assume that τ(·), the
density function of ψ(p¯U), is continuously differentiable with bounded derivatives and bounded
away from zero on the interval [ψ−1(ρl), ψ−1(ρu)] ⊂ (0, 1). We also assume that the marker
values are bounded, (β′0, γ
′
0)
′ belongs to a compact set Ω. For the bandwidth h, we assume that
h = O(n−v), 1/5 < v < 1/2.
We first note that from Uno et al. (2007), we have
|β̂ − β0|+ |γ̂ − γ0| = Op(n− 12 ).
It follows that |η(q)l (s)− η¯(q)l (s)| = Op(1), where
η
(q)
l (s) = E(M̂
(q)
li | p̂U = s), M̂ (q)li = I{p̂{Ui,Vi} ∈ [ν0, ν1), Yi = q},
η¯
(q)
l (s) = E(M
(q)
li |p¯U = s), M (q)li = I{p¯{Ui,Vi} ∈ [ν0, ν1), Yi = q}, p¯{U,V } = g2(γ′0W ).
It is also important to note that E{ωs(T0, X,W )} = E{s(T0, X,W )} for any function s(·, ·, ·),
where ω = I(T ≤ t0)∆/G(T ) + I(T > t0)/G(t0).
We next derive the asymptotic theory for η̂
(q)
l (·) when l = 1 and q = 1, but note that the
same arguments can be used to establish the asymptotic theory for other quantities. For the
ease of notation, in Appendix A and B, we suppress the subscript l and supscript (q) from M̂
(q)
li
and M
(q)
li .
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A Uniform Consistency of η̂
(1)
1 (·)
At any given s, let {â(s), b̂(s)}′ be the root of the estimating equation
n∑
i=1
 1
h−1Êi(s)
Kh{Êi(s)}ω̂i [M̂i − g0{a+ bÊi(s)}] = 0,
a(s) = g−10 {η(1)1 (s)}, b(s) = d[g−10 {η(1)1 (s)}]/ds = η˙(1)1 (s)/g˙0{a(s)}, and
d̂(s) =
 d̂a(s)
d̂b(s)
 =
 â(s)− a(s)
h−1{b̂(s)− b(s)}
 .
Our objective is to show that d̂(s)→ 0 in probability as n→∞. To this end, we note that for
any given s, d̂(s) is the solution to the estimating equation Ŝ(d, s) = 0, where d = (da, db)′,
Ŝ(d, s) =
Ŝ1(d; s)
Ŝ2(d; s)
 = n−1 n∑
i=1
 1
h−1Êi(s)
Kh{Êi(s)}ωi [M̂i − G{d, s;ψ(p̂Ui), h}] ,
and
G(d, s; y, h) = g0[a(s) + b(s){y − ψ(s)}+ da + dbh−1{y − ψ(s)}].
The first step is to show that Ŝ(d; s) is uniformly consistent for
S(d; s) =
S1(d; s)
S2(d; s)
 = τ{ψ(s)}
η(1)1 (s)− ∫ K(t)g0{a(s) + da + dbt}dt
− ∫ tK(t)g0{a(s) + da + dbt}dt

We first show that
sup
s
∣∣∣∣∣n−1
n∑
i=1
Kh{Êi(s)}ω̂iM̂i − τ{ψ(s)}η(1)1 (s)
∣∣∣∣∣
and
sup
d,s
∣∣∣∣ n−1 n∑
i=1
Kh{Êi(s)}ω̂iG{d, s;ψ(p̂Ui), h} − τ{ψ(s)}
∫
K(t)g0{a(s) + da + dbt}dt
∣∣∣∣
are both Op{(nh)− 12 log(n)}. To this end, we note that since
sup
u
|Ĝ(u)−G(u)| = Op(n− 12 ) (A·1)
16
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(Kalbfleisch & Prentice, 2002) and |β̂ − β0| = Op(n− 12 ),∣∣∣∣∣n−1
n∑
i=1
(ω̂i − ωi)Kh{Êi(s)}G{d, s;ψ(p̂Ui), h}
∣∣∣∣∣ ≤ n−1
n∑
i=1
|ω̂i − ωi|Kh{Êi(s)} = Op(n− 12 ).
This, together with the convergence of n
1
2 (β̂ − β0), implies that∣∣∣∣ n−1 n∑
i=1
Kh{Êi(s)}ω̂iG{d, s;ψ(p̂Ui), h} − τ{ψ(s)}
∫
K(t)g0{a(s) + da + dbt}dt
∣∣∣∣
≤
∣∣∣∣ n− 12 ∫ Kh{y − ψ(s)}G(d, s; y, h)dGn [ωI{ψ(p̂U) ≤ y} − ωI{ψ(p¯U) ≤ y}] ∣∣∣∣
+
∣∣∣∣ ∫ Kh{y − ψ(s)}G(d, s; y, h)dP [ωI{ψ(p̂U) ≤ y}]− τ{ψ(s)} ∫ K(t)g0{a(s) + da + dbt}dt ∣∣∣∣
+
∣∣∣∣ n− 12 ∫ Kh{y − ψ(s)}dGn [ωG{d, s;ψ(p¯U), h}I{ψ(p¯U) ≤ y}] ∣∣∣∣ +Op(n− 12 )
. n− 12h−1‖Gn‖Hδ+
∣∣∣∣ n− 12 ∫ Kh{y − ψ(s)}dGn [ωG{d, s;ψ(p¯U), h}I{ψ(p¯U) ≤ y}] ∣∣∣∣ +Op(n− 12 + h2)
where Hδ = {ωI[ψ{g1(β′x)} ≤ c]− ωI[ψ{g1(β′0x)} ≤ c] : ‖β − β0‖ ≤ δ, y} is a class of functions
indexed by β and c. Furthermore, Hδ is uniformly bounded by an envelop function in the order
of δ
1
2 with respect to L2 norm. By the maximum inequality of Van der vaart and Wellner (1996),
we have
E‖Gn‖Hδ . δ
1
2 (| log(δ)|+ | log(h)|)
(
1 +
δ
1
2 (| log(δ)|+ | log(h)|)
δn
1
2
)
.
This, coupled with the fact that |β̂ − β0| = Op(n− 12 ), implies that
n−
1
2h−1‖Gn‖Hδ . Op{(nh)−
1
2 (nh2)−
1
4 log(n)}.
Secondly, with the standard arguments used in Bickel & Rosenblatt (1973), it can be shown
that ∣∣∣∣n− 12 ∫ Kh{x− ψ(s)}dGn [ωG{d, s;ψ(p¯U), h}I{ψ(p¯U) ≤ x}] ∣∣∣∣= Op{(nh)− 12 log(n)}.
Therefore, for h = n−v, 1/5 < v < 1/2,
sup
d,s
∣∣∣∣ n−1 n∑
i=1
Kh{Êi(s)}ω̂iG{d, s;ψ(p̂Ui), h} − τ{ψ(s)}
∫
K(t)g0{a(s) + da + dbt}dt
∣∣∣∣
17
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is Op{(nh)− 12 log(n)}. Following from (A·1), |γ̂− γ0| = Op(n− 12 ), and similar arguments as given
above, we have
sup
s
∣∣∣∣∣n−1
n∑
i=1
Kh{Êi(s)}ω̂iM̂i − τ{ψ(s)}η(1)1 (s)
∣∣∣∣∣ = Op{(nh)− 12 log(n)},
and hence supd,s |Ŝ1(d, s) − S1(d, s)| = Op{(nh)−
1
2 log(n)} = op(1). It follows from the same
arguments as given above that supd,s |Ŝ2(d, s) − S2(d, s)| = Op{(nh)−
1
2 log(n) + h} = op(1).
Therefore supd,s |Ŝ(d, s)−S(d, s)| = op(1). This uniform convergence, coupled with the fact that
0 is the unique solution to the equation S(d, s) = 0 with respect to d and all the eigenvalues of
A(s) = −∂S(d; s)/∂d′|d=0 = τ{ψ(s)}g˙0{a(s)}diag{1,
∫
v2K(v)dv} are uniformly bounded above
zero, suggests that sups |d̂(s)| = Op{(nh)−
1
2 log(n) + h} = op(1), which implies the consistency
of η̂
(1)
1 (s) = g0{â(s)}.
B Asymptotic distribution of η̂
(1)
1 (·)
It follows from a Taylor series expansion that
(nh)
1
2 d̂a(s) = (nh)
1
2{â(s)− a(s)} = Â1(s)′(nh) 12 Ŝ(0; s) +Op
{
(nh)
1
2 (|d̂a(s)|2 + |d̂b(s)|2)
}
,
where Â1(s) is the first row of Â(s) = −{∂Ŝ(d; s)/∂d′}−1|d=0. Using the similar arguments in the
previous section, one can show that Â1(s) converges to A1(s), the first row of A(s), uniformly in
s. Furthermore, with the convergence rate of Ŝ(d, s), it is not difficult to show that the remainder
term is bounded by Op
{
(nh)−
1
2 log(n)2 + (nh)
1
2h2
}
uniformly in s. It follows that
(nh)
1
2 d̂a(s) = A1(s)′(nh)
1
2 Ŝ(0; s) +Op
{
(nh)−
1
2 log(n)2 + (nh)
1
2h2
}
)
=
(nh)
1
2 Ŝ10; s)
τ{ψ(s)}g˙0{a(s)} +Op
{
(nh)−
1
2 log(n)2 + (nh)
1
2h2
}
.
This, together with the convergence rate of Ŝ1(0; s), implies sups |d̂a(s)| = Op{(nh)−
1
2 log(n)}.
It follows that (nh)
1
2 d̂a(s) is asymptotically equivalent to
(nh)
1
2Pn
(
Kh{Ê(s)}ω
[
M̂ − G0{s, ψ(p̂U)}
])
τ{ψ(s)}g˙0{a(s)} .
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where G0(s, y) = g0[a(s) + b(s){y − ψ(s)}]. We next show that (nh) 12 d̂a(s) is asymptotically
equivalent to
(nh)
1
2 d˜a(s) =
(nh)
1
2Pn (Kh{E(s)}ω [M − G0{s, ψ(pU)}])
τ{ψ(s)}g˙0{a(s)} ,
i.e., p̂U and p̂{U,V } can be replaced by their respective p¯U and p¯{U,V } in d̂a(s), where E(s) =
ψ(p¯U) − ψ(s). To this end, noticing the fact that τ{ψ(s)}g˙0{a(s)} is bounded away from zero
uniformly in s, we have
(nh)
1
2
∣∣∣d̂a(s)− d˜a(s)∣∣∣ . h 12 ∣∣∣∣∫ Kh{x− ψ(s)}dGn [ωM̂I{ψ(p̂U) ≤ x} − ωMI{ψ(p¯U) ≤ x}]∣∣∣∣
+ h
1
2
∣∣∣∣∫ Kh{x− ψ(s)}G0(s, x)dGn [ωI{ψ(p̂U) ≤ x} − ωI{ψ(p¯U) ≤ x}]∣∣∣∣
+
∣∣∣∣(nh) 12 ∫ Kh{x− ψ(s)}dP [ω{M̂ − G0(s, p̂U)}I{ψ(p̂U) ≤ x}]∣∣∣∣
. h− 12‖Gn‖Fδ + h−
1
2‖Gn‖Hδ +Op{(nh)
1
2 |β̂ − β0|+ |γ̂ − γ0|+ h2}
where Fδ =
{
ωyI{g2(γ′w) ∈ [ν0, ν1)}I[ψ{g1(β′x)} ≤ c]−ωyI{g2(γ′0w) ∈ [ν0, ν1)}I[ψ{g1(β′0x)} ≤
c]
}
: |γ−γ0|+ |β−β0| ≤ δ, c} is the class of functions indexed by γ, β and c. By the maximum in-
equality and the fact that |β̂−β0|+|γ̂−γ0| = Op(n− 12 ), we have h− 12‖Gn‖Fδ = Op{h−
1
2n−
1
4 log(n)}.
It follows that (nh)
1
2 d̂a(s)−(nh) 12 d˜a(s) is asymptotic op(1) uniformly in s. This, together with the
standard arguments for local linear regression fitting, implies that (nh)
1
2{â(s)− a(s)} converges
to a normal with mean 0 and variance σ2(s)g˙0{a(s)}−2, where m2 =
∫
K(s)2ds and
σ2(s) =
m2
τ 2{ψ(s)}E
[
{M − η(1)1 (s)}2
G(T0 ∧ t0)
∣∣∣∣ p¯U = s
]
It follows from the delta method that (nh)
1
2{η̂(1)1 (s) − η(1)1 (s)} is asymptotically normal with
mean 0 and variance σ2(s). To justify the resampling method, we note that conditional on the
data the random variable
(nh)
1
2Pn
[
Kh{Ê(s)}ω̂
{
M̂ − η̂(1)1 (s)
}
Z
]
τ̂{ψ(s)}
is asymptotical normally distributed with mean zero and variance
σ̂2(s) =
hPn
[
Kh{Ê(s)}2ω̂2
{
M̂ − η̂(1)1 (s)
}2]
τ̂ 2{ψ(s)} .
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It follows from the arguments given in Appendix A to show that which converges to σ2(s), as
n→∞.
C Asymptotic null distribution of D̂(s)
From Appendix A, sups |D̂(s)−
∑L
l=1 w˜l{η(1)l (s)− ηl(s)ξ(s)}| → 0 in probability as n→∞. Fur-
thermore, as n→∞, (nh) 12 [D̂(s)−∑Ll=1 w˜l{η(1)l (s)− ηl(s)ξ(s)}] can be uniformly approximated
by
(nh)
1
2
L∑
l=1
w˜l
[
{η̂(1)l (s)− η(1)l (s)} −
1∑
q=0
{η̂(q)l (s)− η(q)l (s)}ξ(s)−
L∑
l′=1
{η̂(1)l′ (s)− η(1)l′ (s)}ηl(s)
]
≈(nh) 12Pn [Kh{E(s)}A(s)] ≈ (nh) 12Pn [Kh{E(s)}A(p¯U)]
where
A(s) = ω
L∑
l=1
1∑
q=0
κ
(q)
l (s)
[
M
(q)
l − g0{a(q)l (s) + b(q)l (s)E(s)}
]
,
κ
(q)
l (s) = q {w˜l − ηl(s)} − ξ(s)w˜l, a(q)l (s) = g−10 {η(q)l (s)}, b(q)l (s) =
η˙
(q)
l (s)
g˙0{a(q)l (s)}
,
Under the null hypothesis, η
(1)
l (s) = ηl(s)ξ(s), l = 1, · · · , L and
(nh)
1
2 D̂(s) ≈ (nh) 12Pn [Kh{E(s)}A(p¯U)] .
Let r(s) = m2E{A(p¯U)2|p¯U = s}dt, and
D̂(s) =
(nh)
1
2
[r(s)τ{ψ(s)}] 12 Pn[A(p¯U)Kh{E(s)}].
By Lemma 1 of Fan and Zhang (1998), we have
pr
[
rn
{
sup
s∈[ρl,ρr]
∣∣∣D̂(s)∣∣∣− dn} < x]→ 1 + exp(−2e−x)
2
,
as n→∞, where
rn = [2 log{(ρr − ρl)/h}] 12 , and dn = rn + r−1n log
{
(4pim2)
−1
∫ 1
−1
K˙(t)2dt
}
.
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This implies that under the null hypothesis,
pr
[
rn
{
sup
s∈[ρl,ρr]
∣∣∣∣∣ (nh)
1
2 D̂(s)
r(s)τ{ψ(s)}
∣∣∣∣∣− dn
}
< x
]
→ 1 + exp(−2e
−x)
2
,
as n→∞. To justify the resampling method for approximating the null distribution, we let
D̂∗(s) = Pn
{
Kh{Ê(s)}
L∑
l=1
w˜l
(
V̂(1)l −
1∑
q=0
V̂(q)l ξ(s)−
L∑
l′=1
V̂(1)l′ ηl(s)
)
Z
}
and r̂(s) = var{D̂∗(s)|O} and O = {(Yi,∆i, Ui, Vi), i = 1, · · · , n)}. It follows the same arguments
as given above that
pr
[
rn
{
sup
s∈Ωh
∣∣∣∣∣ (nh)
1
2D∗(s)
r̂(s)τ̂{ψ(s)}
∣∣∣∣∣− dn
}
< x
∣∣∣∣ O
]
→ 1 + exp(−2e
−x)
2
,
as the sample size goes to infinity. Therefore, we can use the conditional distribution of
sup
s∈Ωh
(nh)
1
2 D̂∗(s)
r̂(s)τ̂{ψ(s)}
to approximate the null distribution of
sup
s∈Ωh
(nh)
1
2 D̂(s)
r(s)τ{ψ(s)} .
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Figure 1: Evaluating CRP incremental values for female participants from Cardiovascular Heath
Study by treating non-CHD death as non-event; (a) Density function estimate of the conventional
risk estimate; (b) Reclassification rate estimates; (c)-(e) η̂
(1)
l (·), l = 1, 2, 3, and corresponding
expected values under the null; (f) Point- and simultaneous-p-value curves
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Figure 2: Evaluating CRP incremental values for female participants from Cardiovascular Heath
Study by treating non-CHD death as censoring event; (a) Density function estimate of the
conventional risk estimate; (b) Reclassification rate estimates; (c)-(e) η̂
(1)
l (·), l = 1, 2, 3, and
corresponding expected values under the null; (f) Point- and simultaneous-p-value curves
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Table 1: Estimates for η̂l, η̂
(0)
l and η̂
(1)
l for female participants from the Cardiovascular Health
Study with various conventional risk estimates (shown in the parenthesis are corresponding
standard error estimates).
(a) Treating non-CHD death as non-event
s η̂l(s) η̂
(1)
l (s) η̂
(0)
l (s)
l=1 0.379(0.025) 0.027(0.009) 0.349(0.025)
0.11 l=2 0.621(0.025) 0.072(0.014) 0.543(0.025)
l=3 0.000(0.000) 0.000(0.000) 0.000(0.000)
l=1 0.000(0.000) 0.000(0.000) 0.000(0.000)
0.18 l=2 0.798(0.017) 0.127(0.014) 0.664(0.020)
l=3 0.202(0.017) 0.050(0.009) 0.150(0.015)
l=1 0.000(0.000) 0.000(0.000) 0.000(0.000)
0.21 l=2 0.407(0.021) 0.052(0.010) 0.349(0.020)
l=3 0.593(0.021) 0.108(0.014) 0.476(0.022)
(b) Treating non-CHD death as censoring event
s η̂l(s) η̂
(1)
l (s) η̂
(0)
l (s)
l=1 0.587(0.023) 0.040(0.015) 0.540(0.024)
0.10 l=2 0.413(0.023) 0.055(0.014) 0.352(0.022)
l=3 0.000(0.001) 0.000(0.000) 0.000(0.001)
l=1 0.000(0.000) 0.000(0.000) 0.000(0.000)
0.21 l=2 0.429(0.021) 0.061(0.015) 0.356(0.019)
l=3 0.571(0.021) 0.130(0.017) 0.426(0.020)
l=1 0.000(0.000) 0.000(0.000) 0.000(0.000)
0.30 l=2 0.009(0.004) 0.000(0.001) 0.009(0.004)
l=3 0.991(0.004) 0.346(0.026) 0.642(0.026)
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